What is it used for?
PEMAZYRE is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test . This indication is approved under accelerated approval based on overall response rate and duration of response . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). PEMAZYRE is indicated for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement.PEMAZYRE is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test . This indication is approved under accelerated approval based on overall response rate and duration of response . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). PEMAZYRE is indicated for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement.
Read the primary sourceThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Product details
- Active ingredient
- pemigatinibpemigatinib
- Form and strength
- TABLET · 4.5 mg; TABLET · 9 mg; TABLET · 13.5 mgTABLET · 4.5 mg; TABLET · 9 mg; TABLET · 13.5 mg
- Manufacturer / applicant
- INCYTE CORPORATIONINCYTE CORPORATION
Tablets: 4.5 mg: round, white to off-white tablet debossed on one side with "I" and "4.5" on the other side. 9 mg: oval, white to off-white tablet debossed on one side with "I" and "9" on the other …Tablets: 4.5 mg: round, white to off-white tablet debossed on one side with "I" and "4.5" on the other side. 9 mg: oval, white to off-white tablet debossed on one side with "I" and "9" on the other …
Safety and clinical review
- Ocular ToxicityOcular Toxicity
- Hyperphosphatemia and Soft Tissue MineralizationHyperphosphatemia and Soft Tissue Mineralization
- Embryo-Fetal ToxicityEmbryo-Fetal Toxicity
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Read the primary sourcePrepare your enquiry
Include the brand or generic name, strength, dosage form, requested quantity and country where care is needed. You can attach a prescription when you continue.
Questions patients ask
What is Pemazyre used for?
PEMAZYRE is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test . This indication is approved under accelerated approval based on overall response rate and duration of response . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). PEMAZYRE is indicated for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement.PEMAZYRE is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test . This indication is approved under accelerated approval based on overall response rate and duration of response . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). PEMAZYRE is indicated for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement.
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Which formulation of Pemazyre should I ask about?
TABLET · 4.5 mg; TABLET · 9 mg; TABLET · 13.5 mgTABLET · 4.5 mg; TABLET · 9 mg; TABLET · 13.5 mg
Read the primary sourceWhat determines the price of Pemazyre?
A current quote depends on the exact presentation, quantity, provider and access arrangements. A catalogue entry is not a stock or delivery promise. Medical charges are paid to the provider, separately from coordination fees.
What should I check before using Pemazyre?
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Sources and review scope
FDA prescribing informationThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.